Translation and Clinical Development of Antithrombotic Aptamers

Nucleic Acid Therapeutics

Volumn 26, Issue 3, 2016, Pages 147-155

  Nimjee, Shahid M ^a   Povsic, Thomas J ^b   Sullenger, Bruce A ^b   Becker, Richard C ^c  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIDOTE; APTAMER; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9A; PEGNIVACOGIN; PROTHROMBIN; THROMBIN; VON WILLEBRAND FACTOR; THROMBOCYTE ACTIVATING FACTOR;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL EVALUATION; DRUG SCREENING; HUMAN; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRECLINICAL STUDY; PRIORITY JOURNAL; THROMBOSIS; BLOOD CLOTTING; DRUG EFFECTS; GENETICS; THROMBOCYTE;

ANTICOAGULANTS; APTAMERS, NUCLEOTIDE; BLOOD COAGULATION; BLOOD PLATELETS; HUMANS; PLATELET ACTIVATING FACTOR; THROMBOSIS;

EID: 84986625953     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2015.0581     Document Type: Article

References (62)

1. Becker RC, TJ Povsic, MG Cohen, CP Rusconi and BA Sullenger. (2010). Nucleic acid aptamers as antithrombotic agents: opportunities in extracellular therapeutics. Thromb Haemost 103:586-595.
2. Nimjee SM, CP Rusconi, RA Harrington and BA Sullenger. (2005). The potential of aptamers as anticoagulants. Trends Cardiovasc Med 15:41-45.
3. Becker RC, S Oney, KCD Becker and BA Sullenger. (2009). Antidote-controlled antithrombotic therapy targeting factor IXa and von Willebrand factor. Ann N Y Acad Sci 1175:61-70.
4. Monroe DM, M Hoffman and HR Roberts. (1996). Transmission of a procoagulant signal from tissue factor-bearing cells to platelets. Blood Coagul Fibrinolysis 7:459-464.
5. Monroe DM. (2002). Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 47:3142-3148.
6. Hoffman M, DM Monroe, JA Oliver and HR Roberts. (1995). Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood 86:1794-1801.
7. Gitel S, R Stephenson and S Wessler. (1977). In vitro and in vivo correlation of clotting protease activity: effect of heparin. Proc Natl Acad Sci U S A 74:3028-3032.
8. Butenas S, T Orfeo, MT Gissel, KE Brummel and KG Mann. (2004). The significance of circulating factor IXa in blood. J Biol Chem 279:22875-22882.
9. Gray E, J Tubbs, TSA Oates, M Bolsclair, G Kemball-Cook and T Barrowcliffe. (1995). Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity. Thromb Haemost 73:675-679.
10. Buyue Y, H Whinna and J Sheehan. (2008). The heparinbinding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis. Blood 112:3234-3241.
11. Sramek A, M Kriek and F Rosendaal. (2003). Decreased mortality of ischaemic heart disease among carriers of haemophilia. Blood 108:52-66.
12. Tuinenburg A, E Mauser-Bunschoten, M Verhaar, D Biesma and R Schutgens. (2009). Cardiovascular disease in patients with hemophilia. J Thromb Haemost 7:247-254.
13. Rothlein R, JM Shen, N Naser, DR Gohimukkula, TB Caligan, RC Andrews, AM Schmidt, EA Rose and AMM Mjalli. (2005). TTP889, a novel orally active partial inhibitor of FIXa inhibits clotting in two A/V shunt models without prolonging bleeding times. Blood (ASH Annual Meeting Abstracts) 106:1886.
14. Howard EL, KCD Becker, CP Rusconi and RC Becker. (2007). Factor IXa inhibitors as novel anticoagulants. Arterioscler Thromb Vasc Biol 27:722-727.
15. Benedict C, J Ryan, B Wolitzky, R Ramos, MP Tijburg and D Stern. (1991). Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest 88:1760-1765.
16. Spanier T, M Oz, J Madigan, E Rose, D Stern, R Nowygrod and A Schmidt. (1997). Selective anticoagulation with active site blocked factor IXa in synthetic patch vascular repair results in decreased blood loss and operative time. ASAIO J 43:M526-M530.
17. Wong A, A Gunn, P Ku, S Hollenbach and U Sinha. (1997). Relative efficacy ofactive site-blocked factors IXa, Xa in models of rabbit venous and arterio-venous thrombosis. Thromb Haemost 77:1143-1147.
18. Eikelboom JW, SL Zelenkofske and CP Rusconi. (2010). Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism. Arterioscler Thromb Vasc Biol 30:382-387.
19. Rusconi CP, JD Roberts, GA Pitoc, SM Nimjee, RR White, G Quick Jr., E Scardino, WP Fay and BA Sullenger. (2004). Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 22:1423-1428.
20. Rusconi CP, E Scardino, J Layzer, GA Pitoc, TL Ortel, D Monroe and BA Sullenger. (2002). RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419:90-94.
21. Gopinath SCB, Y Shikamoto, H Mizuno and PKR Kumar. (2006). A potent anti-coagulant RNA aptamer inhibits blood coagulation by specifically blocking the extrinsic clotting pathway. Thromb Haemost 95:767-771.
22. Nimjee SM, JR Keys, GA Pitoc, G Quick, CP Rusconi and BA Sullenger. (2006). A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol Ther 14:408-415.
23. Dyke CK, SR Steinhubl, NS Kleiman, RO Cannon, LG Aberle, M Lin, SK Myles, C Melloni, RA Harrington, et al. (2006). First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: A phase 1a pharmacodynamic evaluation of a drug-Antidote pair for the controlled regulation of factor IXa activity. Circulation 114:2490-2497.
24. Chan MY, MG Cohen, CK Dyke, SK Myles, LG Aberle, M Lin, J Walder, SR Steinhubl, IC Gilchrist, et al. (2008). Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 117:2865-2874.
25. Povsic T, M Cohen, M Chan, S Zelenkofske, W Wargin, R Harrington, J Alexander, C Rusconi and R Becker. (2011). Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: Translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design. J Thromb Thrombolysis 32:21-31.
26. Chan MY, CP Rusconi, JH Alexander, RM Tonkens, RA Harrington and RC Becker. (2008). A randomized, repeatdose, pharmacodynamic and safety study of an antidotecontrolled factor IXa inhibitor. J Thromb Haemost 6: 789-796.
27. Cohen MG, DA Purdy, JS Rossi, LR Grinfeld, SK Myles, LG Aberle, AB Greenbaum, E Fry, MY Chan, et al. (2010). First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous intervention. Circulation 122:614-622.
28. Povsic TJ, MG Cohen, R Mehran, CE Buller, C Bode, JH Cornel, JD Kasprzak, G Montalescot, D Joseph, et al. (2011). A randomized, partially-blinded, multicenter, activecontrolled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR phase IIb trial. Am Heart J 161:261-268.
29. Povsic TJ, WA Wargin, JH Alexander, J Krasnow, M Krolick, MG Cohen, R Mehran, CE Buller, C Bode, et al.; RADAR Investigators. (2011). Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy. Eur Heart J 32:2412-2419.
30. Povsic TJ, JP Vavalle, LH Aberle, JD Kasprzak, MG Cohen, R Mehran, C Bode, CE Buller, G Montalescot, et al. (2013). A phase 2, randomized, partially blinded, activecontrolled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. Eur Heart J 34:2481-2489.
31. Ganson NJ, TJ Povsic, BA Sullenger, JH Alexander, SL Zelenkofske, JM Sailstad, CP Rusconi and MS Hershfield. (2015). Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer. J Allergy Clin Immunol [Epub ahead of print]; DOI: 10.1016/j.jaci.2015.10.034
32. Schellekens H, W Hennink and V Brinks. (2013). The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res 30:1729-1734.
33. Yang Q and SK Lai. (2015). Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip Rev Nanomed Nanobiotechnol 7:655-677.
34. Gabriel RS, YM Smyth, V Menon, AL Klein, RA Grimm, JD Thomas and EM Sabik. (2008). Safety of ultrasound contrast agents in stress echocardiography. Am J Cardiol 102:1269-1272.
35. Wei K, SL Mulvagh, L Carson, R Davidoff, R Gabriel, RA Grimm, S Wilson, L Fane, CA Herzog, et al. (2008). The safety of deFinity and Optison for ultrasound image enhancement: A retrospective analysis of 78, 383 administered contrast doses. J Am Soc Echocardiogr 21:1202-1206.
36. Lincoff AM, R Mehran, TJ Povsic, SL Zelenkofske, Z Huang, PW Armstrong, PG Steg, C Bode, MG Cohen, et al. (2016). Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): A randomized clinical trial. Lancet 387 (10016):349-356.
37. Layzer JM and BA Sullenger. (2007). Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. Oligonucleotides 17:1-11.
38. Bompiani KM, DM Monroe, FC Church and BA Sullenger. (2012). A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. J Thromb Haemost 10: 870-880.
39. Bock LC, LC Griffin, JA Latham, EH Vermaas and JJ Toole. (1992). Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355: 564-566.
40. DeAnda A Jr., SE Coutre, MR Moon, CM Vial, LC Griffin, VS Law, M Komeda, LL Leung and DCMiller. (1994). Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. Ann Thorac Surg 58:344-350.
41. Griffin LC, GF Tidmarsh, LC Bock, JJ Toole and LL Leung. (1993). In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 81:3271-3276.
42. White R, C Rusconi, E Scardino, A Wolberg, J Lawson, M Hoffman and B Sullenger. (2001). Generation of species cross-reactive aptamers using toggle SELEX. Mol Ther 4:567-573.
43. Nimjee SM, S Oney, Z Volovyk, KM Bompiani, SB Long, M Hoffman and BA Sullenger. (2009). Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. RNA 12:2105-2111.
44. Soule EE, KM Bompiani, RS Woodruff and BA Sullenger. (2015). Targeting two coagulation cascade proteases with a bivalent aptamer yields a potent and antidote-controllable anticoagulant. Nucleic Acid Ther [Epub ahead of print]; DOI: 10.1089/nat.2015.0565
45. Rusconi CP, A Yeh, HK Lyerly, JH Lawson and BA Sullenger. (2000). Blocking the initiation of coagulation by RNA aptamers to factor VIIa. Thromb Haemost 84:841-848.
46. Woodruff RS, Y Xu, J Layzer, W Wu, ML Ogletree and BA Sullenger. (2013). Inhibiting the intrinsic pathway of coagulation with a factor XII-Targeting RNA aptamer. J Thromb Haemost 11:1364-1373.
47. No authors. (1988). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 332:349-360.
48. Wallentin LC. (1991). Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-Term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. J Am Coll Cardiol 18:1587-1593.
49. Kandzari DE, V Hasselblad, JE Tcheng, GW Stone, RM Califf, A Kastrati, FJ Neumann, SJ Brener, G Montalescot, DF Kong and RA Harrington. (2004). Improved clinical outcomes with abciximab therapy in acute myocardial infarction: A systematic overview of randomized clinical trials. Am Heart J 147:457-462.
50. Simoons ML; GUSTO IV-ACS Investigators. (2001). Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial. Lancet 357:1915-1924.
51. Giugliano RP, JA White, C Bode, PW Armstrong, G Montalescot, BS Lewis, A van t Hof, LG Berdan, KL Lee, et al. (2009). Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 360:2176-2190.
52. Boersma E, RA Harrington, DJ Moliterno, H White, P Théroux, F Van de Werf, A de Torbal, PW Armstrong, LC Wallentin, et al. (2002). Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-Analysis of all major randomised clinical trials. Lancet 359:189-198.
53. Huang RH, DH Fremont, JL Diener, RG Schaub and JE Sadler. (2009). A structural explanation for the antithrombotic activity of ARC1172, a DNA aptamer that binds von Willebrand factor domain A1. Structure 17:1476-1484.
54. Markus HS, C McCollum, C Imray, MA Goulder, J Gilbert and A King. (2011). The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: A randomized trial. Stroke 42:2149-2153.
55. Jilma-Stohlawtez P, JC Gilbert, M Gorczyca, P Knobl and B Jilma. (2011). A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with conge nital thrombotic thrombocytopenic purpura. Thromb Haemost 106:539-547.
56. Oney S, SM Nimjee, J Layzer, N Que-Gewirth, D Ginsburg, RC Becker, G Arepally and BA Sullenger. (2007). Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. Oligonucleotides 17:265-274.
57. Nimjee SM, JD Lohrmann, H Wang, DJ Snyder, TJ Cummings, RC Becker, S Oney and BA Sullenger. (2012). Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor. Mol Ther 20:391-397.
58. Bompiani KM, RS Woodruff, RC Becker, SM Nimjee and BA Sullenger. (2012). Antidote control of aptamer therapeutics: The road to a safer class of drug agents. Curr Pharm Biotechnol 13:1924-1934.
59. Griffin LC, JJ Toole and LL Leung. (1993). The discovery and characterization of a novel nucleotide-based thrombin inhibitor. Gene 137:25-31.
60. Nimjee SM, JR Keys, GA Pitoc, G Quick, CP Rusconi and BA Sullenger. (2006). A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol Ther 14:408-415.
61. Vavalle JP, C Rusconi, S Zelenkofske, JH Alexander and RC Becker. (2011). Thrombin generation kinetics of the REG2 anticoagulation system: A first-in-human experience. Circulation 124:A13826.
62. Vavalle JP, CP Rusconi, S Zelenkofske, WA Wargin, JH Alexander and RC Becker. (2012). A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent. J Thromb Haemost 10:1303-1311.